G1 Therapeutics CEO John Bailey's 2022 pay falls 65% to $3M
G1 Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 26, 2023
G1 Therapeutics reported fiscal year 2022 executive compensation information on April 26, 2023.
In 2022, three executives at G1 Therapeutics received on average a compensation package of $1.8M, a 55% decrease compared to previous year.
Average pay of disclosed executives at G1 Therapeutics
John E. Bailey, Jr, Chief Executive Officer, received $3M in total, which decreased by 65% compared to 2021. 49% of Bailey's compensation, or $1.5M, was in option awards. Bailey also received $287K in non-equity incentive plan, $764K in salary, $492K in stock awards, as well as $9.2K in other compensation.
For fiscal year 2022, the median employee pay was $243,930 at G1 Therapeutics. Therefore, the ratio of John E. Bailey, Jr's pay to the median employee pay was 12 to one.
Jennifer K. Moses, Chief Financial Officer, received a compensation package of $1.1M, which decreased by 25% compared to previous year. 41% of the compensation package, or $465K, was in salary.
Mark Avagliano, Chief Business Officer, earned $1.1M in 2022, a 25% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 26, 2023.